1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60D27E1A716F0FBED6525817C002FC068
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-best-practices-collection-utilization-valuation-real-world-data?opendocument
18
19opendocument
2035.175.120.174
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Data Management and Biostatics

Real World Data and Medical Affairs: Best Practices in Collection, Utilization and Valuation of Real World Data

ID: 5472


Features:

22 Info Graphics

23 Data Graphics

480+ Metrics


Pages/Slides: 53


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt fromReal World Data and Medical Affairs: Best Practices in Collection, Utilization and Valuation of Real World Data”

STUDY OVERVIEW


As the pharmaceutical industry's use of real world data rises, regulators, payers, physicians and patients are increasingly expecting pharma companies to demonstrate the effectiveness of new medicines. Pharmaceutical companies, in turn, are relying on their Medical Affairs function to oversee the collection and utilization of real world data for informing key stakeholders on product effectiveness.

However, it is challenging for Medical Affairs groups to harness relevant information from huge data sources such as electronic medical records, clinical trial data, and patient behavior data. Equally difficult is the task of assimilating this information in a way that presents a clear outcomes picture in terms of cause and effect.

Best Practices, LLC undertook benchmarking research to understand Medical Affairs' role in the collection, analysis and dissemination of RWD. Additionally, this study probes the pros and cons of various forms of RWD and lessons learned in utilizing it.


This study includes two segments: Regional Segment: US-Only (N= 8), Global (N= 12) and Company-Size Segments: Large Companies (N= 18) and Small and Mid-sized Companies (N= 10).

KEY TOPICS


Collection of Real World Data:
  • Challenges in Collecting and Evaluating Real World Data
  • Sources of Data
  • Vendors for Collecting Real World Data

Utilization of Real World Data:
  • Current Use of Real World Data
  • Future Use of Real World Data
  • Barriers to Use of Real World Data
  • Improving Medical Affairs’ Use of Real World Data
  • Strategic Use of Real World Data by Medical Affairs

Valuation of Real World Data:
  • Valuable Real World Data Activities
  • Pros & Cons of Forms of Real World Data
  • Lessons Learned

KEY METRICS

  • What challenges does Medical Affairs face in collecting and evaluating the use of Real World Data in the function?
  • What percentage of Real World Data collected falls under the following categories - internal (self-generated data), external (purchased data) and external (free data)?
  • Who are your external vendors for collecting Real World Data?
  • How does your Medical Affairs group currently use Real World Data?
  • When does your Medical Affairs group currently use Real World Data?
  • In the next 2 years, how will Medical Affairs more use Real World Data?
  • What barriers will limit Medical Affairs use of Real World Data?
  • How can Medical Affairs improve its use of Real World Data?
  • How does your Medical Affairs group make use of Real World Data in supporting its strategy?
  • How valuable are the listed Real World Data activities to Medical Affairs' success?

SAMPLE KEY FINDINGS

  • Data Interpretation and Data Analysis are Among the Most Valuable Real World Data Activities that Contribute to the Success of the Medical Affairs Function: Real World Data activities pertaining to data analysis and insight generation are most valuable to Medical Affairs, irrespective of company size. Additionally, data generation, identification and acquisition are also deemed highly valuable by benchmark respondents.

METHODOLOGY


Best Practices, LLC engaged 28 Medical Affairs leaders from 23 leading biopharmaceutical companies through a benchmarking survey. More than 75% of participants serve at the director level or above.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Abbvie; Allergan; Ambry Genetics; AstraZeneca; Bayer; Biogen; Celgene; EMD Serono; Ferring Pharmaceuticals; Genentech; Incyte; Kyowa Kirin; Merck; Novartis; Pfizer; Roche; Sanofi; Santen; Sunovion; Takeda Pharmaceuticals; Theravance; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.